Compare · OUST vs TMO
OUST vs TMO
Side-by-side comparison of Ouster Inc. (OUST) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OUST and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $183.61B, about 354.3x OUST ($518.2M).
- Over the past year, OUST is up 143.6% and TMO is up 16.8% - OUST leads by 126.7 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 15 for OUST).
- TMO has more recent analyst coverage (25 ratings vs 18 for OUST).
- Company
- Ouster Inc.
- Thermo Fisher Scientific Inc
- Price
- $38.88+0.96%
- $484.60-1.94%
- Market cap
- $518.2M
- $183.61B
- 1M return
- +45.50%
- +7.02%
- 1Y return
- +143.57%
- +16.83%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 17
- Recent ratings
- 18
- 25
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest OUST
- Ouster BlueCity Unveils 500-Foot Advanced Detection with REV8 Native Color Lidar, Defining a New Era for Intelligent Transportation Systems
- Ouster Completes New Jersey DOT Deployment of Ouster BlueCity Ahead of 2026 FIFA World Cup
- Ouster and FieldAI Collaborate to Scale Autonomous Perception for the World's Most Challenging Environments with REV8 Digital Lidar
- SEC Form SD filed by Ouster Inc.
- Roth Capital initiated coverage on Ouster with a new price target
- Chief Revenue Officer Jacquemet Cyrille sold $377,320 worth of shares (9,433 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 123,158 units (SEC Form 4)
- Chief Technology Officer Frichtl Mark exercised 50,063 shares at a strike of $14.22 and sold $15,606,971 worth of shares (384,426 units at $40.60) as part of a pre-agreed trading plan, decreasing direct ownership by 53% to 294,924 units (SEC Form 4)
- Chief Operating Officer Spencer Darien sold $1,350,022 worth of shares (30,000 units at $45.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 342,366 units (SEC Form 4)
- SEC Form 144 filed by Ouster Inc.
- ARGUS Interception and Ouster Announce Strategic Agreement to Strengthen the Precision and Reliability of Counter-UAS Systems with Digital Lidar
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)